细胞动力科技 CYTK 深 沪
等待开盘 02-07 09:30:00 美东时间
62.32
+2.080
+3.45%
华盛通- 最 高67.095
- 今 开61.31
- 成交量 111.36万股
- 最 低 58.85
- 昨 收 60.24
- 总市值 533.78万
- 52周最高 70.98
- 市盈率 静 --
- 换手率 1300.15%
- 52周最低 29.31
- 委 比 42.86%
- 总股本 8.57万
- 历史最高 110.25
- 量 比 0.78
- 振 幅 13.69%
- 历史最低 1.10
- 每 手 1
- 风险率 12.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cytokinetics Wins FDA Nod For Heart Drug Myqorzo
FDA approved CYTK's Myqorzo for oHCM. It reduces heart's pumping ability, has a warning for heart failure and expected to launch in 2026.
2025-12-23 00:23
Market-Moving News for December 22nd
CYTK: 8% | Cytokinetics shares were trading higher after the company announced that the FDA approved MYQORZO, 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic
2025-12-22 20:38
Cytokinetics将发行可转换优先票据筹集最多5.5亿美元
周三盘前，生物制药公司Cytokinetics（CYTK）上涨0.6%，此前该公司宣布，计划通过发行2031年到期的可转换优先票据筹集最多5.5亿美元资金。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-09-17 20:42
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics granted stock options and RSUs to 11 new employees as an inducement to employment. The company is focused on developing cardiovascular therapies, including aficamten, omeccamiv mecarbil, and CK-586, for various heart conditions.
2025-06-17 20:00
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Cytokinetics公司宣布启动2025年度企业捐赠计划，计划向符合条件的美国非营利组织提供慈善捐赠，支持心血管疾病领域的健康公平、科学教育中的多样性以及为本地和高风险社区提供的基本服务。申请截止日期为2025年8月4日，申请链接已提供。
2025-06-10 11:30
Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer
Cytek Biosciences unveiled the Cytek Aurora™ Evo system, a next-generation full spectrum flow cytometer offering improved sample throughput, automation capabilities, and enhanced detection of small particles. Building on the trusted performance of the Cytek Aurora system, the Aurora Evo empowers researchers with high-speed workflows and consistent data quality to accelerate discoveries in cell analysis.
2025-05-29 21:00
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
Cytokinetics, Inc. announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025. The company is advancing a pipeline of potential new cardiovascular medicines, including aficamten, omeacamptiv mecarbil, CK-586, and CK-089, targeting various heart conditions and muscle dysfunction. A webcast of the event will be available on the company’s website.
2025-05-29 20:00
Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference
Cytek Biosciences will participate in the Goldman Sachs 46th Global Healthcare Conference on June 11 in Miami Beach, with management set to join a fireside chat at 11:40 a.m. PT / 2:40 p.m. ET. The company, headquartered in Fremont, California, specializes in advanced cell analysis solutions and offers products for research and clinical use in specific regions.
2025-05-28 20:05
Cantor Fitzgerald Reiterates Overweight on Cytokinetics
Cantor Fitzgerald analyst Charles Duncan reiterates Cytokinetics (NASDAQ:CYTK) with a Overweight.
2024-09-10 01:00
Cytokinetics' CK-586 Advances After Phase 1 Results, Phase 2 Trial Set for Late 2024
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that data from the Phase 1 study of CK-4021586 (CK-586) were presented in a poster session at the American College of Clinical Pharmacology (ACCP) Annual Meeting
2024-09-09 19:33
